|
Age (years)
|
34 (19.25–44.5)
|
32 (27–42.5)
|
36 (30–46)
|
0.15
|
|
Gender (male)
|
31 (70 %)
|
14 (67 %)
|
17 (74 %)
|
0.74
|
|
Nadir CD4a
|
54 (17–96)
|
73 (30–177)
|
23 (14–84)
|
0.04
|
|
Viral load (×103 copies/mm3)b
|
113,637 (2,995–365,663)
|
35,149 (212.3–300,184)
|
169,133 (35,405–419,382)
|
0.13
|
|
Length of time since HIV diagnosis (months)
|
5 (1–60)
|
1 (1–16)
|
28 (1–72)
|
0.03
|
|
cART use while in the ICU
|
17 (38.6 %)
|
10 (48 %)
|
7 (30 %)
|
0.35
|
|
Mechanical ventilation use on ICU day 1
|
21 (48 %)
|
8 (42 %)
|
13 (52 %)
|
0.56
|
|
Vasoactive drug use on ICU day 1
|
12 (26 %)
|
5 (24 %)
|
7 (27 %)
|
0.99
|
|
SAPS II score (points)
|
47 (37–55)
|
48 (37–57)
|
46 (38–54)
|
0.27
|
|
SOFA score on day 1 (points)
|
4 (1–8)
|
1 (0–7)
|
5 (2–8)
|
0.08
|
|
Isolated TB pulmonary presentation
|
22 (50 %)
|
10 (48 %)
|
12 (52 %)
|
1.00
|
|
Disseminated TB presentation
|
22 (50 %)
|
11 (52 %)
|
11 (48 %)
|
1.00
|
|
TB treatment before ICU admission
|
25 (57 %)
|
11 (52 %)
|
14 (61 %)
|
0.76
|
|
TB treatment
| | | | |
|
- only by enteral drugs
|
16 (36 %)
|
10 (48 %)
|
6 (26 %)
|
0.21
|
|
- adding intravenous drugs
|
28 (64 %)
|
11 (52 %)
|
17 (74 %)
| |
|
TB treatment: Δ ICU admission
|
0 (-5–+21)
|
-5 (-23–+2)
|
-5 (-21–0)
|
0.09
|
|
TB treatment before ICU
|
25 (57 %)
|
11 (52.4 %)
|
14 (61 %)
|
0.76
|
|
Organ Dysfunctions
| | | | |
|
Cardiovascular
|
18 (41 %)
|
7 (33.3 %)
|
11 (48 %)
|
0.37
|
|
Respiratory
|
15 (34 %)
|
5 (24 %)
|
10 (43 %)
|
0.21
|
|
Renal
|
14 (32 %)
|
5 (24 %)
|
9 (39 %)
|
0.34
|
|
Neurological
|
13 (29 %)
|
3 (14 %)
|
10 (43 %)
|
0.04
|
|
Hepatic
|
9 (20 %)
|
5 (24 %)
|
4 (17 %)
|
0.71
|
|
Hematological
|
9 (20 %)
|
3 (14 %)
|
6 (26 %)
|
0.46
|
